Somapacitan Once-Weekly Compared to Daily Norditropin® for Pediatric Growth Hormone Deficiency in Phase 3 Trial
Background
Children diagnosed with Growth Hormone Deficiency (GHD) experience impaired growth and development, necessitating long-term hormone replacement therapy. The current standard of care, recombinant human growth hormone (rhGH), typically requires daily subcutaneous injections, which can be burdensome for children and their families, potentially leading to poor adherence and suboptimal treatment outcomes. Developing a long-acting growth hormone formulation, such as somapacitan, that can be administered less frequently, offers a significant advantage by potentially improving patient compliance, reducing injection fatigue, and enhancing overall quality of life.
Study Design
This completed Phase 3, randomized, open-label, active-controlled, multinational trial (REAL4) enrolled 110 Chinese children with Growth Hormone Deficiency. Participants were randomly assigned to receive either somapacitan once-weekly or Norditropin® (daily rhGH) once-daily. The study aimed to investigate the efficacy and safety of the once-weekly somapacitan regimen compared to the established daily Norditropin® treatment. The trial had a total duration of 4 years, involving 19 clinic visits and 1 phone call, to thoroughly assess long-term outcomes, safety, tolerability, pharmacokinetics, and pharmacodynamics.
Results
The provided abstract describes the study design and objectives but does not include specific efficacy or safety results from the completed trial. Researchers aimed to test how well somapacitan works and its safety profile compared to Norditropin®. Detailed findings regarding growth velocity, height standard deviation scores, adverse events, or other primary and secondary endpoints are not yet publicly available in this abstract.
Why It Matters
A successful once-weekly growth hormone therapy like somapacitan could significantly reduce the treatment burden for children with GHD and their caregivers, potentially leading to improved adherence and better long-term growth outcomes. Switching from daily to weekly injections could enhance the quality of life for young patients, making the management of a chronic condition more manageable. If proven effective and safe, somapacitan could become a preferred treatment option, simplifying protocols and potentially improving patient satisfaction and clinical outcomes. The clinical translation outlook is promising, as this is a completed Phase 3 trial, suggesting that regulatory submission could follow if results are positive.
somapacitan
norditropin
growth-hormone-deficiency
pediatric
phase-3-trial
rct